Blue Water: Preclinical Data on 'Monkeypox Vaccine Utilizing Novirus Virus-Like Particle'

 Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.

In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform. Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood. Initial data show that mice were able to generate an immune response following vaccination and antibodies were able to neutralize the vaccinia virus. Vaccinia, the virus responsible for smallpox disease, belongs to the same family as monkeypox virus and has shown high levels of cross-reactivity with monkeypox.

https://www.biospace.com/article/releases/blue-water-biotech-announces-preclinical-data-supporting-immunogenicity-of-novel-monkeypox-vaccine-utilizing-norovirus-virus-like-particle-platform/